Trinity Biotech (NASDAQ: TRIB) shareholders back all AGM resolutions

Rhea-AI Filing Summary

Trinity Biotech plc reports that shareholders approved all resolutions put forward at its annual general meeting held on September 30, 2025, each passing with at least 93% of votes cast. This indicates very strong support for the proposals presented to investors.

The company also notes that Jim Walsh retired by rotation from the board of directors in line with the company’s constitution, after more than 30 years of service. Trinity Biotech expresses its gratitude for his long-standing contributions and explains that he will continue to support the company’s management team in a new capacity as a Scientific Advisor.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 6-K: How Foreign Companies Report to the SEC →

Accepted by SEC EDGAR 09/30/2025 - 04:00 PM Learn about SEC filing dates

FAQ

What did Trinity Biotech plc (TRIB) announce in this Form 6-K?

Trinity Biotech plc announced the results of its annual general meeting, stating that all resolutions proposed were approved by shareholders with strong support and that a long-serving director, Jim Walsh, retired from the board and will continue as a Scientific Advisor.

Were all resolutions approved at Trinity Biotech plc’s September 30, 2025 AGM?

Yes. Trinity Biotech plc reports that shareholders approved all resolutions proposed at the annual general meeting, with each resolution receiving at least 93% of votes cast.

What happened to director Jim Walsh at the Trinity Biotech plc 2025 AGM?

Jim Walsh retired by rotation from Trinity Biotech plc’s board of directors at the annual general meeting, in accordance with the company’s constitution, after more than 30 years of service.

Will Jim Walsh remain involved with Trinity Biotech plc (TRIB) after retiring from the board?

Yes. Trinity Biotech plc states that Jim Walsh has agreed to continue to support the company’s management team as a Scientific Advisor following his retirement from the board.

What level of shareholder support did Trinity Biotech plc’s AGM resolutions receive?

The company notes that all resolutions received strong backing, with a minimum approval level of 93% of votes cast by shareholders present or represented at the meeting.

Is this Trinity Biotech plc Form 6-K linked to any registration statements?

Yes. The company states that this Form 6-K is being incorporated by reference into its Registration Statements on Form S-8 with file numbers 333-182279, 333-195232 and 333-253070.

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549

F O R M 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of September 2025

TRINITY BIOTECH PLC

(Name of Registrant)

IDA Business Park

Bray, Co. Wicklow, Ireland

(Address of Principal Executive Office)

Indicate by check mark whether the registrant files or will file annual reports under cover of

Form 20-F or Form 40-F.

Form 20-F ☒    Form 40-F ☐

This Form 6-K is being incorporated by reference into our Registration Statements on Form S-8 (File Nos. 333-182279, 333-195232 and 333-253070).

Trinity Biotech plc Announces Results of Annual General Meeting

At the annual general meeting (the “Meeting”) of the Company held on September 30 2025, shareholders approved all of the resolutions proposed by the requisite majorities and with a minimum approval of 93% of votes cast.

The resolutions (the text of which is more fully set out in the notice of meeting dated September 4 2025) were as follows:

1. To re-appoint Grant Thornton as statutory auditor of the Company to hold office until the conclusion of the next annual general meeting at which accounts are laid before the Company.

2. To authorise the board of directors to fix the statutory auditors’ remuneration.

3. To reduce the nominal (par) value of each of the Company’s A Ordinary Shares.

4. To increase the Company’s authorised share capital.

5. To refresh the board of directors’ authority to allot and issue new shares in the Company.

6. To refresh the board of directors’ authority to allot and issue new shares for cash without applying Irish statutory pre-emption rights.

Jim Walsh retired by rotation from the Company’s board of directors at the Meeting in accordance with the Company’s constitution. The Company would like to express its sincere gratitude to Jim for his many contributions and his commitment over more than 30 years of service.  The Company is also grateful that Jim has agreed to continue to support the Company’s management team as a Scientific Advisor.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	TRINITY BIOTECH PLC
		Trinity Biotech plc
		(Registrant)
	By:	/s/ Susan O’Connor
		Susan O’Connor Chief Financial Officer

Date:  September 30, 2025